268 related articles for article (PubMed ID: 26980242)
1. Development of an experimental rat model of hyperammonemic encephalopathy and evaluation of the effects of rifaximin.
Tamaoki S; Suzuki H; Okada M; Fukui N; Isobe M; Saito T
Eur J Pharmacol; 2016 May; 779():168-76. PubMed ID: 26980242
[TBL] [Abstract][Full Text] [Related]
2. Hyperammonemic coma after hepatectomy in germ-free rats.
Schalm SW; van der Mey T
Gastroenterology; 1979 Aug; 77(2):231-4. PubMed ID: 447036
[TBL] [Abstract][Full Text] [Related]
3. Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity.
Kaji K; Takaya H; Saikawa S; Furukawa M; Sato S; Kawaratani H; Kitade M; Moriya K; Namisaki T; Akahane T; Mitoro A; Yoshiji H
World J Gastroenterol; 2017 Dec; 23(47):8355-8366. PubMed ID: 29307995
[TBL] [Abstract][Full Text] [Related]
4. Pharmacotherapy for hyperammonemia.
Hadjihambi A; Khetan V; Jalan R
Expert Opin Pharmacother; 2014 Aug; 15(12):1685-95. PubMed ID: 25032885
[TBL] [Abstract][Full Text] [Related]
5. [Prevention and treatment of hepatic encephalopathy].
Sivolap YP
Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(10):144-147. PubMed ID: 29171503
[TBL] [Abstract][Full Text] [Related]
6. Treatment of hyperammonemia in liver failure.
Jover-Cobos M; Khetan V; Jalan R
Curr Opin Clin Nutr Metab Care; 2014 Jan; 17(1):105-10. PubMed ID: 24281376
[TBL] [Abstract][Full Text] [Related]
7. Rifaximin for treatment of hepatic encephalopathy.
Maclayton DO; Eaton-Maxwell A
Ann Pharmacother; 2009 Jan; 43(1):77-84. PubMed ID: 19092143
[TBL] [Abstract][Full Text] [Related]
8. Rifaximin versus neomycin on hyperammoniemia in chronic portal systemic encephalopathy of cirrhotics. A double-blind, randomized trial.
Pedretti G; Calzetti C; Missale G; Fiaccadori F
Ital J Gastroenterol; 1991 May; 23(4):175-8. PubMed ID: 1751811
[TBL] [Abstract][Full Text] [Related]
9. [Effect of lactitol (NS-4) on the increase in blood and brain ammonia concentration and on coma in newly developed rat models of hepatic coma].
Watanabe M; Ozaki T; Hirata Y; Yoshikuni Y; Kimura K
Nihon Yakurigaku Zasshi; 1995 Feb; 105(2):97-109. PubMed ID: 7737597
[TBL] [Abstract][Full Text] [Related]
10. Taurine treatment preserves brain and liver mitochondrial function in a rat model of fulminant hepatic failure and hyperammonemia.
Jamshidzadeh A; Heidari R; Abasvali M; Zarei M; Ommati MM; Abdoli N; Khodaei F; Yeganeh Y; Jafari F; Zarei A; Latifpour Z; Mardani E; Azarpira N; Asadi B; Najibi A
Biomed Pharmacother; 2017 Feb; 86():514-520. PubMed ID: 28024286
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study.
Kircheis G; Nilius R; Held C; Berndt H; Buchner M; Görtelmeyer R; Hendricks R; Krüger B; Kuklinski B; Meister H; Otto HJ; Rink C; Rösch W; Stauch S
Hepatology; 1997 Jun; 25(6):1351-60. PubMed ID: 9185752
[TBL] [Abstract][Full Text] [Related]
12. Protective effect of L-carnitine in ammonia-precipitated encephalopathy in the portacaval shunted rat.
Therrien G; Rose C; Butterworth J; Butterworth RF
Hepatology; 1997 Mar; 25(3):551-6. PubMed ID: 9049197
[TBL] [Abstract][Full Text] [Related]
13. Visual evoked potentials in a rabbit model of hepatic encephalopathy. II. Comparison of hyperammonemic encephalopathy, postictal coma, and coma induced by synergistic neurotoxins.
Pappas SC; Ferenci P; Schafer DF; Jones EA
Gastroenterology; 1984 Mar; 86(3):546-51. PubMed ID: 6693016
[TBL] [Abstract][Full Text] [Related]
14. Optimal treatment of hepatic encephalopathy.
Waghray A; Waghray N; Kanna S; Mullen K
Minerva Gastroenterol Dietol; 2014 Mar; 60(1):55-70. PubMed ID: 24632768
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms, diagnosis and management of hepatic encephalopathy.
Prakash R; Mullen KD
Nat Rev Gastroenterol Hepatol; 2010 Sep; 7(9):515-25. PubMed ID: 20703237
[TBL] [Abstract][Full Text] [Related]
16. Hyperammonemia induces neuroinflammation that contributes to cognitive impairment in rats with hepatic encephalopathy.
Rodrigo R; Cauli O; Gomez-Pinedo U; Agusti A; Hernandez-Rabaza V; Garcia-Verdugo JM; Felipo V
Gastroenterology; 2010 Aug; 139(2):675-84. PubMed ID: 20303348
[TBL] [Abstract][Full Text] [Related]
17. Quinolinate in brain and cerebrospinal fluid in rat models of congenital hyperammonemia.
Robinson MB; Heyes MP; Anegawa NJ; Gorry E; Djali S; Mellits ED; Batshaw ML
Pediatr Res; 1992 Oct; 32(4):483-8. PubMed ID: 1279510
[TBL] [Abstract][Full Text] [Related]
18. Management of hepatic encephalopathy: role of rifaximin.
Zeneroli ML; Avallone R; Corsi L; Venturini I; Baraldi C; Baraldi M
Chemotherapy; 2005; 51 Suppl 1():90-5. PubMed ID: 15855752
[TBL] [Abstract][Full Text] [Related]
19. Memantine, a noncompetitive NMDA receptor antagonist improves hyperammonemia-induced encephalopathy and acute hepatic encephalopathy in rats.
Vogels BA; Maas MA; Daalhuisen J; Quack G; Chamuleau RA
Hepatology; 1997 Apr; 25(4):820-7. PubMed ID: 9096582
[TBL] [Abstract][Full Text] [Related]
20. Treatment of Overt Hepatic Encephalopathy.
Sussman NL
Clin Liver Dis; 2015 Aug; 19(3):551-63. PubMed ID: 26195208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
